Hybio Pharmaceutical Co.Ltd(300199)
Short form equity change report
Name of listed company: Hybio Pharmaceutical Co.Ltd(300199) place of stock listing: Shenzhen Stock Exchange Stock abbreviation: Hybio Pharmaceutical Co.Ltd(300199) Stock Code: 300199 name of information disclosure obligor: Lai Jiansheng mailing address: runheng Royal Park, No. 68 Luotian Road, Bao'an District, Shenzhen nature of share change: reduction of shareholding ratio (below 5%)
Signed on: January 25, 2022
Statement of information disclosure obligor
1. The information disclosure obligor shall, in accordance with the securities law of the people's Republic of China (hereinafter referred to as the "Securities Law"), the measures for the administration of the acquisition of listed companies (hereinafter referred to as the "acquisition measures"), the standards for the contents and forms of information disclosure by companies offering securities to the public No. 15 - Report on changes in equity (hereinafter referred to as the "Standards No. 15") and relevant laws This report is prepared according to laws and regulations.
2. The information disclosure obligor has obtained necessary authorization and approval for signing this report;
3. In accordance with the provisions of the securities law, the acquisition measures and Standard No. 15, this report has fully disclosed the changes in the shares in which the information disclosure obligor has an interest in Hybio Pharmaceutical Co.Ltd(300199) (the following reduction of "company" or " Hybio Pharmaceutical Co.Ltd(300199) "); As of the signing date of this report, except for the information disclosed in this report, the above information disclosure obligor has not increased or reduced its shares in Hybio Pharmaceutical Co.Ltd(300199) by any other means.
4. This equity change is based on the information stated in this report. Except for the information disclosed in this report, the information disclosure obligor has not entrusted or authorized any other person to provide the information not listed in this report and make any explanation or explanation to this report.
5. The information disclosure obligor promises that there are no false records, misleading statements or major omissions in this report, and is legally responsible for the authenticity, accuracy and completeness.
catalogue
Section 1 interpretation Section 2 Introduction to information disclosure obligors four
1、 Basic information of information disclosure obligor four
2、 Information disclosure obligors holding shares of other listed companies Section III purpose of equity change and shareholding plan of information disclosure obligor four
1、 Purpose of equity change of information disclosure obligor five
2、 Share increase and decrease plan of the information disclosure obligor in the next 12 months 5 Section IV equity change method six
1、 The way of this equity change six
2、 Shareholding of information disclosure obligor six
3、 Restrictions on the rights of shares held by the information disclosure obligor six
4、 The impact of this equity change on listed companies six
5、 Other information Section V information disclosure obligors' purchase and sale of shares of Listed Companies in the first six months Section VI other major matters nine
1、 Other matters to be disclosed nine
2、 The disclosure obligor declares that nine
3、 Documents for future reference nine
4、 Reference place of documents for future reference Section VII declaration of information disclosure obligor 10 schedule eleven
Section I interpretation
In this report, unless otherwise specified, the following abbreviations have the following meanings in this report:
Information disclosure obligor refers to Lai Jiansheng
Listed company, Hybio Pharmaceutical Co.Ltd(300199) refers to Hybio Pharmaceutical Co.Ltd(300199)
This equity change refers to the reduction of 13000000 shares of listed companies held by information disclosure obligors through block trading
Report, this report and this report refer to the Hybio Pharmaceutical Co.Ltd(300199) simplified equity change report
Yuan means RMB yuan
CSRC or CSRC means China Securities Regulatory Commission
Shenzhen Stock Exchange and stock exchange refer to Shenzhen Stock Exchange
China Securities Depository and Clearing Corporation refers to Shenzhen Branch of China Securities Depository and Clearing Corporation Limited
Securities Law refers to the securities law of the people's Republic of China
The measures for the administration of acquisition refers to the measures for the administration of the acquisition of listed companies
Standard No. 15 refers to Standard No. 15 on the contents and forms of information disclosure by companies offering securities to the public - Report on changes in equity
Section II introduction to information disclosure obligors
1、 Basic information of information disclosure obligor
Information disclosure obligor: Lai Jiansheng;
Gender: male;
Nationality: Chinese
ID number: 44052719**********;
Mailing address: runheng royal garden, No. 68 Luotian Road, Bao'an District, Shenzhen;
Residency in other countries or regions: none.
2、 Information disclosure obligors holding equity of other listed companies
As of the date of signing this report, the information disclosure obligor does not hold or control more than 5% of the total shares issued by other domestic or overseas listed companies.
Section III purpose of equity change and shareholding plan of information disclosure obligor
1、 Purpose of equity change of information disclosure obligor
The purpose of this equity change is the capital demand of the information disclosure obligor.
2、 Share increase and decrease plan of the information disclosure obligor in the next 12 months
As of the signing date of this report, the information disclosure obligors have reduced their holdings of 13000000 tradable shares of the listed company with unlimited conditions through block trading, accounting for 1.4178% of the total share capital of the listed company.
In addition, the information disclosure obligor may continue to reduce its equity shares in the listed company in the next 12 months; In case of relevant equity changes, the information disclosure obligor will perform the obligation of information disclosure in strict accordance with relevant regulations.
Section IV changes in equity
1、 Method of this equity change
Reduction of holdings of shares during the reduction period, reduction of holdings of shares, reduction of shareholding proportion, shareholder name, mode, nature of shares, inter price (yuan), number (shares) (%) source
Lai Jiansheng's block agreement unlimited sales terms January 16, 2022 13000,0 1.4178% transaction transferee circulating shares June 24 00
2、 Shareholding of information disclosure obligor
Shares held before the reduction name of shareholders holding shares after the reduction number of shares (shares) in total share capital number of shares (shares) in total share capital proportion (%)
Total shares held 45846352 5.00 32846352 3.5822%
Including: unlimited sales
Lai Jiansheng 45846352 5.00 32846352 3.5822% shares
Shares with limited sales conditions 0
Before this equity change,; Lai Jiansheng holds 45846352 tradable shares of listed companies with unlimited sales conditions
Shares, accounting for 5.00% of the total share capital of the listed company; After this equity change, Lai Jiansheng held 32846352 tradable shares of the listed company without sale conditions, accounting for 3.58% of the total share capital of the listed company, and is no longer a shareholder holding more than 5% of the listed company.
3、 Restrictions on the rights of shares held by the information disclosure obligor
As of the date of signing this report, the shares of the listed company held by the information disclosure obligor have not been pledged, frozen or restricted by other rights.
4、 Impact of this equity change on Listed Companies
This equity change will not lead to the change of the actual controller of the listed company and will not affect the governance of the listed company
Impact on management structure and going concern.
5、 Other information
This equity change complies with the securities law of the people's Republic of China, the measures for the administration of the acquisition of listed companies, several provisions on the reduction of shares held by shareholders, directors, supervisors and senior managers of listed companies, the stock listing rules of Shenzhen Stock Exchange, and the guidelines for the operation of the regulations of listed companies of Shenzhen Stock Exchange In accordance with the detailed rules for the implementation of share reduction by shareholders, directors, supervisors and senior managers of listed companies of Shenzhen Stock Exchange and other relevant laws, regulations and normative documents, there is no violation of rules and commitments.
Section V information disclosure obligors' trading of shares of Listed Companies in the first six months; information disclosure obligors' failure to trade shares of listed companies through centralized trading at stock exchanges in the six months before signing this report.
Section VI other major matters
1、 Other matters to be disclosed
In addition to the information disclosed in this report, the information disclosure obligor has no other information that should be disclosed in order to avoid misunderstanding of the content of the report, as well as other information required by the CSRC or the stock exchange to be provided by the information disclosure obligor according to law.
2、 Statement of information disclosure obligor
The information disclosure obligor promises that there are no false records, misleading statements or major omissions in this report, and will bear individual and joint legal liabilities for its authenticity, accuracy and completeness.
3、 Documents for future reference
1. Identity information of the information disclosure obligor;
2. The text of this report signed by the information disclosure obligor;
3. Other documents.
4、 Reference place of documents for future reference
This report and documents for future reference are placed in the Hybio Pharmaceutical Co.Ltd(300199) securities management department for investors' reference.
Contact: Yang Di
Tel: 0755-26588036
Fax: 0755-26588078
Contact address: Hanyu biomedical park, Central District, high tech Industrial Park, Nanshan District, Shenzhen
Section VII declaration of information disclosure obligor
The information disclosure obligor promises that there are no false records, misleading statements or major omissions in the Hybio Pharmaceutical Co.Ltd(300199) simplified equity change report, and will bear individual and joint legal liabilities for its authenticity, accuracy and completeness.
Information disclosure obligor: Lai Jiansheng Signature Date: January 25, 2022 schedule
Short form equity change report
Basic information
Name of Listed Company Shenzhen Hybio Pharmaceutical Co.Ltd(300199) Co., Ltd. listed company office Shenzhen
Say the company is on the ground
Stock abbreviation Hybio Pharmaceutical Co.Ltd(300199) stock code 300199
Information disclosure Yi Lai Jiansheng information disclosure Yi Shenzhen
Name and registered place of the agent
Add □
Whether the decrease of ownership interest is consistent with that of the bank
The number of shares changed √□√ unchanged, but the shareholders changed
□
Meaning of information disclosure
Whether the agent is whether the agent is √ listed company □√ listed company □
A major shareholder controller
Block trading through stock exchange √ agreement transfer □
Administrative transfer or change of state-owned shares □ indirect transfer □
The equity changing party obtains the new shares issued by the listed company and executes the court ruling
Formula (multiple choices) □□
Inheritance □ gift
